A first-in-human, randomized, controlled, subject- and reviewer-blinded multicenter study of Actamax™ Adhesion Barrier

• Published in: Archives of gynecology and obstetrics 2017-02, Vol.295 (2), p.383-395
• Main Authors: Trew, Geoffrey H., Pistofidis, George A., Brucker, Sara Y., Krämer, Bernhard, Ziegler, Nicole M., Korell, Matthias, Ritter, Henning, McConnachie, Alex, Ford, Ian, Crowe, Alison M., Estridge, Trudy D., Diamond, Michael P., De Wilde, Rudy L.
• Format: Article
• Language: English
• Subjects: Adhesion; Adult; Endocrinology; Female; General Gynecology; Gynecologic Surgical Procedures - adverse effects; Gynecology; Human Genetics; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate - administration & dosage; Hydrogels; Laparoscopy; Laparoscopy - adverse effects; Medicine; Medicine & Public Health; Obstetrics/Perinatology/Midwifery; Polyethylene Glycols - administration & dosage; Postoperative Complications - etiology; Prospective Studies; Surgery; Tissue Adhesions - prevention & control; Uterine Myomectomy - adverse effects
• ISSN: 0932-0067; 1432-0711
• DOI: 10.1007/s00404-016-4211-x

Purpose Post-surgical adhesions remain a significant concern following abdominopelvic surgery. This study was to assess safety, manageability and explore preliminary efficacy of applying a degradable hydrogel adhesion barrier to areas of surgical trauma following gynecologic laparoscopic abdominopelvic surgery. Methods This first-in-human, prospective, randomized, multicenter, subject- and reviewer-blinded clinical study was conducted in 78 premenopausal women (18–46 years) wishing to maintain fertility and undergoing gynecologic laparoscopic abdominopelvic surgery with planned clinically indicated second-look laparoscopy (SLL) at 4–12 weeks. The first two patients of each surgeon received hydrogel, up to 30 mL sprayed over all sites of surgical trauma, and were assessed for safety and application only ( n  = 12). Subsequent subjects ( n  = 66) were randomized 1:1 to receive either hydrogel (Treatment, n  = 35) or not (Control, n  = 31); 63 completed the SLL. Results No adverse event was assessed as serious, or possibly device related. None was severe or fatal. Adverse events were reported for 17 treated subjects (17/47, 36.2%) and 13 Controls (13/31, 41.9%). For 95.7% of treated subjects, surgeons found the device “easy” or “very easy” to use; in 54.5%, some residual material was evident at SLL. For 63 randomized subjects who completed the SLL, adjusted between-group difference in the change from baseline adhesion score demonstrated a 41.4% reduction for Treatment compared with Controls ( p  = 0.017), with a 49.5% reduction ( p  = 0.008) among myomectomy subjects ( n  = 34). Conclusion Spray application of a degradable hydrogel adhesion barrier during gynecologic laparoscopic abdominopelvic surgery was performed easily and safely, without evidence of clinically significant adverse outcomes. Data suggest the hydrogel was effective in reducing postoperative adhesion development, particularly following myomectomy.